US 11,732,241 B2
Methods of producing in vitro liver constructs and uses thereof
Anthony Atala, Winston-Salem, NC (US); Colin Bishop, Clemmons, NC (US); and Ivy Mead, Inman, KS (US)
Assigned to Wake Forest University Health Sciences, Winston-Salem, NC (US)
Appl. No. 15/768,293
Filed by Wake Forest University Health Sciences, Winston-Salem, NC (US)
PCT Filed Oct. 14, 2016, PCT No. PCT/US2016/056942
§ 371(c)(1), (2) Date Apr. 13, 2018,
PCT Pub. No. WO2017/070007, PCT Pub. Date Apr. 27, 2017.
Claims priority of provisional application 62/241,966, filed on Oct. 15, 2015.
Prior Publication US 2018/0320141 A1, Nov. 8, 2018
Int. Cl. C12N 5/071 (2010.01); C12M 3/00 (2006.01); G01N 33/50 (2006.01); B33Y 10/00 (2015.01)
CPC C12N 5/0671 (2013.01) [B33Y 10/00 (2014.12); C12M 21/08 (2013.01); C12N 5/067 (2013.01); G01N 33/5088 (2013.01); C12N 2502/14 (2013.01); C12N 2503/02 (2013.01)] 24 Claims
 
1. An artificial liver construct comprising:
a cell composition, the cell composition comprising, in combination:
(a) hepatocyte cells in an amount by number of from 70 to 90 percent;
(b) Kupffer cells in an amount by number of from 5 to 20 percent;
(c) hepatic stellate cells in an amount by number of from 2 to 10 percent;
(d) sinusoidal endothelial cells in an amount by number of from 2 to 10 percent; and
(e) cholangiocyte cells in an amount by number of from 1 to 4 percent.